PCM
JANX icon

Pinz Capital Management’s Janux Therapeutics JANX Stock Holding History

Pinz Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-32,100
Closed -$801K – 266
2021
Q2 		$801K Buy
+32,100
New +$715K 0.24% 84

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Pinz Capital Management's JANX Position: Q3 2021 in Review

Pinz Capital Management sold out of Janux Therapeutics (JANX) in Q3 2021, closing a stake of 32,100 shares — an estimated $801K sold.

Pinz Capital Management first reported a position in JANX in Q2 2021 and held it in 1 quarter. The position peaked at $801K in Q2 2021. 45 funds tracked by Wall St. Rank hold JANX as of Q3 2021.

  • Pinz Capital Management reported no remaining Janux Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 32,100 Janux Therapeutics shares in Q3 2021, an estimated $801K.
  • Pinz Capital Management first reported a position in Janux Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Janux Therapeutics position peaked at $801K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.